Pura Vida Investments LLC acquired a new stake in Sesen Bio Inc (NASDAQ:SESN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,000 shares of the company’s stock, valued at approximately $284,000. Pura Vida Investments LLC owned about 0.26% of Sesen Bio at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Bridgeway Capital Management Inc. bought a new stake in shares of Sesen Bio in the 3rd quarter valued at approximately $215,000. Nexthera Capital LP bought a new stake in shares of Sesen Bio in the 3rd quarter valued at approximately $2,531,000. Vanguard Group Inc lifted its stake in shares of Sesen Bio by 22.0% in the 3rd quarter. Vanguard Group Inc now owns 2,518,891 shares of the company’s stock valued at $5,415,000 after purchasing an additional 454,950 shares during the last quarter. Northern Trust Corp bought a new stake in shares of Sesen Bio in the 2nd quarter valued at approximately $315,000. Finally, Vanguard Group Inc. lifted its stake in shares of Sesen Bio by 22.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,518,891 shares of the company’s stock valued at $5,415,000 after purchasing an additional 454,950 shares during the last quarter. 39.37% of the stock is owned by institutional investors and hedge funds.
Shares of SESN stock opened at $0.97 on Friday. Sesen Bio Inc has a 52-week low of $0.66 and a 52-week high of $3.50. The company has a market cap of $76.29 million, a P/E ratio of -1.76 and a beta of 2.01.
Several research firms have recently issued reports on SESN. HC Wainwright set a $1.00 price objective on Sesen Bio and gave the company a “hold” rating in a research note on Tuesday, March 5th. Zacks Investment Research raised Sesen Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Sesen Bio in a research note on Wednesday, February 6th. Finally, ValuEngine lowered Sesen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $2.00.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by PressOracle and is the property of of PressOracle. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://pressoracle.com/news/2019/03/17/pura-vida-investments-llc-purchases-new-holdings-in-sesen-bio-inc-sesn.html.
About Sesen Bio
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.
Further Reading: Market Capitalization and Individual Investors
Want to see what other hedge funds are holding SESN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sesen Bio Inc (NASDAQ:SESN).
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.